Published in Acta Pharm Sin B on June 06, 2015
12-Week Study of Plecanatide for CIC (The CIC3 Study) | NCT01982240
Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice. Acta Pharm Sin B (2016) 0.75
Patient considerations in the management of chronic constipation: focus on prucalopride. Patient Prefer Adherence (2016) 0.75
Luminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents. Front Pharmacol (2017) 0.75
Functional bowel disorders. Gastroenterology (2006) 20.72
Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol (2004) 4.89
Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav (2002) 4.54
Chloride channels as drug targets. Nat Rev Drug Discov (2008) 3.22
A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol (2011) 2.81
Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu Rev Physiol (2000) 2.77
SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol (2004) 2.33
Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol (2011) 2.19
Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology (2009) 1.89
Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol (2009) 1.87
Systematic review: impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther (2010) 1.80
Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther (2012) 1.79
CLC chloride channels and transporters: a biophysical and physiological perspective. Rev Physiol Biochem Pharmacol (2007) 1.77
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol (2010) 1.74
Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation. Am J Gastroenterol (2010) 1.70
Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci (2013) 1.61
Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology (2009) 1.59
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther (2010) 1.56
Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology (2010) 1.53
Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol (2005) 1.44
Saturation kinetics applied to in vitro effects of low prostaglandin E2 and F 2 alpha concentrations on ion transport across human jejunal mucosa. Gastroenterology (1980) 1.39
Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther (2012) 1.36
Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol (1993) 1.29
A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil (2010) 1.27
Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol (2009) 1.26
Lubiprostone: a chloride channel activator. J Clin Gastroenterol (2007) 1.24
Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci (2009) 1.19
Recent advances in the understanding of bile acid malabsorption. Br Med Bull (2009) 1.18
Basolateral ClC-2 chloride channels in surface colon epithelium: regulation by a direct effect of intracellular chloride. Gastroenterology (2004) 1.15
Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil (2009) 1.14
Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7 alpha-hydroxylase. Metabolism (2004) 1.07
Non-systemic drugs: a critical review. Curr Pharm Des (2012) 1.02
SC-435, an ileal apical sodium co-dependent bile acid transporter (ASBT) inhibitor lowers plasma cholesterol and reduces atherosclerosis in guinea pigs. Atherosclerosis (2003) 0.99
Function and dysfunction of mammalian membrane guanylyl cyclase receptors: lessons from genetic mouse models and implications for human diseases. Handb Exp Pharmacol (2009) 0.92
Contractile effects and intracellular Ca2+ signalling induced by motilin and erythromycin in the circular smooth muscle of human colon. Neurogastroenterol Motil (2001) 0.88
The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.88
Treatment of constipation with chenodeoxycholic acid. J Int Med Res (1983) 0.88
Treatment of chronic constipation with colchicine: randomized, double-blind, placebo-controlled, crossover trial. Am J Gastroenterol (2003) 0.87
Differential effects of 5-hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors: an operational framework to explain and quantify organ-specific behavior. J Pharmacol Exp Ther (2006) 0.87
The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol (2011) 0.86
Linaclotide: first global approval. Drugs (2012) 0.86
Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)). Biochem Biophys Res Commun (2012) 0.86
Therapeutic applications of guanylate cyclase-C receptor agonists. Curr Opin Drug Discov Devel (2002) 0.85
Effect of oral erythromycin on colonic transit in patients with idiopathic constipation. A pilot study. Dig Dis Sci (1995) 0.85
Colchicine is effective for short-term treatment of slow transit constipation: a double-blind placebo-controlled clinical trial. Int J Colorectal Dis (2009) 0.84
Glucuronidation converting methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) to a potent apical sodium-dependent bile acid transporter inhibitor, resulting in a hypocholesterolemic action. J Pharmacol Exp Ther (2007) 0.83
Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial. Aliment Pharmacol Ther (1997) 0.81
Elobixibat for the treatment of constipation. Expert Opin Investig Drugs (2012) 0.81
Misoprostol is effective treatment for patients with severe chronic constipation. Dig Dis Sci (1994) 0.79
Traditional Chinese formula, lubricating gut pill, stimulates cAMP-dependent CI(−) secretion across rat distal colonic mucosa. J Ethnopharmacol (2010) 0.79
Phase II drugs under clinical investigation for the treatment of chronic constipation. Expert Opin Investig Drugs (2014) 0.78
Treatment of functional constipation with the Yun-chang capsule: a double-blind, randomized, placebo-controlled, dose-escalation trial. J Gastroenterol Hepatol (2010) 0.78
Targeting bile acids in the treatment of constipation. Expert Rev Gastroenterol Hepatol (2011) 0.78
Effect of colchicine on jejunal adenylate cyclase activity, PGE2 and cAMP contents. Eur J Pharmacol (1980) 0.77
GM-611 (Chugai Pharmaceutical). Curr Opin Investig Drugs (2001) 0.76
Mitemcinal (GM-611), an orally active motilin agonist, facilitates defecation in rabbits and dogs without causing loose stools. Neurogastroenterol Motil (2007) 0.76